Moreover, there is a meta-analysis suggesting that visfatin/eNampt may be a promising biomarker not only for predicting obesity, diabetes status, insulin resistance, or metabolic syndrome but also for the development of cardiovascular disease35. This evidence concerns the gene NAMPT and metabolic syndrome.